Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399)
XSHE XSHE Primary Summary
002399 Chart
People also search for
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ever had a stock split?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Li Li CEO | XSHE Exchange | CNE100000P02 ISIN |
| CN Country | 1,926 Employees | 18 Jun 2026 Last Dividend | 13 Jun 2016 Last Split | - IPO Date |
Overview
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, the People's Republic of China, is a notable entity in the global pharmaceutical landscape, engaging in the manufacture and sale of a broad spectrum of pharmaceutical products. The company has established a significant presence not only in its domestic market, Mainland China, but also internationally, with operations stretching across Hong Kong, the United States, and Europe. Shenzhen Hepalink's operations are segmented into four main categories: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. Originally operating under the name Shenzhen Hepalink Pharmaceutical Co.,Ltd., the company underwent a rebranding in February 2017 to its current name, reflecting its broader pharmaceutical ventures and group structure. It touts a comprehensive portfolio that spans from research and development to manufacturing and sales, emphasizing its prowess in heparin production and other biopharmaceutical technologies.
Products and Services
- Finished dose pharmaceutical products
- Active Pharmaceutical Ingredients (API)
- Contract Development and Manufacturing Organization (CDMO)
- Other Products and Services
These include a variety of drugs ready for patient use, with a spotlight on their enoxaparin sodium injection, a widely used anticoagulant for the prevention of blood clots.
Hepalink specializes in producing critical API products, including heparin sodium and enoxaparin sodium APIs, utilized in the creation of anticoagulant medications vital for various medical treatments.
Providing extensive services in research and development, manufacturing, quality management, and program management, the company assists in the development and manufacture of recombinant pharmaceutical products, critical non-viral vectors for gene therapy, intermediates, and naturally derived pharmaceutical products.
This includes the production of pancreatin API and various activities beyond direct pharmaceutical manufacturing, such as property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities. The company also extends its expertise to the research, development, production, and sale of biopharmaceuticals, heparin sodium production, pharmaceutical-related service provision, and the trading of medical and biopharmaceutical products.
